Treatment of pro-B acute lymphoblastic leukemia and severe plaque psoriasis with anti-CD19 CAR T cells: a case report

被引:0
|
作者
Zhang, Ao [1 ,2 ]
Zhang, Guangji [1 ,2 ]
Yang, Huihui [1 ,2 ]
Gong, Bengfa [1 ,2 ]
Li, Shouyun [1 ,2 ]
Wei, Na [1 ,2 ]
Xue, Hui [1 ,2 ]
Wei, Hui [1 ,2 ]
Wang, Jianxiang [1 ,2 ]
Qiu, Shaowei [1 ,2 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis,Haihe Lab Cell Ecosyst, Tianjin, Peoples R China
[2] Tianjin Inst Hlth Sci, Tianjin, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2025年 / 16卷
关键词
pro-B ALL; psoriasis; CD19 CAR T cells; B cell; therapeutic targets;
D O I
10.3389/fimmu.2025.1529745
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We report on a rare case of adult pro-B acute lymphoblastic leukemia (pro-B ALL) accompanied with severe refractory plaque psoriasis treated using autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. An 18-year-old man with a known history of mild plaque psoriasis for 1 year was diagnosed with pro-B ALL. After induction chemotherapy, his psoriasis began to worsen. Extensive erythema and desquamation developed on the whole body, with severe plaque psoriasis on the knees and elbows, which did not respond to topical therapy. The application of CAR T-cell therapy not only enabled the patient to achieve deep complete remission (CR) but also allowed his skin lesions to completely subside. This successful treatment supports a potential pathogenic link between B cells and psoriasis, which could provide a new option for overcoming refractory psoriasis.
引用
收藏
页数:5
相关论文
共 50 条
  • [41] A phase I clinical trial of autologous, anti-CD19 gene targeted T cells for adults with B cell acute lymphoblastic leukemia (B-ALL)
    Davila, Marco L.
    Riviere, Isabelle
    Wang, Xiuyan
    Bartido, Shirley
    Stefanski, Jolanta
    Taylor, Clare
    Olszewska, Malgorzata
    Borquez-Ojeda, Oriana
    Qu, Jinrong
    Wasielewska, Teresa
    Frattini, Mark G.
    Sadelain, Michel
    Brentjens, Renier J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] Anti-CD19 CAR T Cells in Refractory Immune Thrombocytopenia of SLE
    Li, Mengtao
    Zhang, Yan
    Jiang, Nan
    Ning, Chun
    Wang, Qian
    Xu, Dong
    Wang, Ziqian
    Lv, Lulu
    Zhou, Daobin
    Zeng, Xiaofeng
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (04): : 376 - 378
  • [43] Sustained Therapeutic Efficacy of Humanized Anti-CD19 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Acute Lymphoblastic Leukemia
    Heng, Gang
    Jia, Jiankun
    Li, Shiqi
    Fu, Gang
    Wang, Meiling
    Qin, Dabing
    Li, Yunyan
    Pei, Li
    Tian, Xiaobo
    Zhang, Jiasi
    Wu, Yi
    Xiang, Shali
    Wan, Jia
    Zhu, Wei
    Zhang, Pei
    Zhang, Qianzhen
    Peng, Xi
    Wang, Linling
    Wang, Ping
    Wei, Zhihao
    Zhang, Yingzi
    Wang, Guiqin
    Chen, Xue
    Zhang, Chengcheng
    Sun, Yanni
    Zhao, Wenxu
    Fan, Yahan
    Yang, Zhi
    Chen, Jieping
    Qian, Cheng
    CLINICAL CANCER RESEARCH, 2020, 26 (07) : 1606 - 1615
  • [44] Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma
    Abramson, Jeremy S.
    McGree, Brianne
    Noyes, Sarah
    Plummer, Sean
    Wong, Curtis
    Chen, Yi-Bin
    Palmer, Edwin
    Albertson, Tina
    Ferry, Judith A.
    Arrillaga-Romany, Isabel C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (08): : 783 - 784
  • [45] Anti-CD19 CAR T cells administration was feasible in a child with primary hepatitis B infection
    Uhlving, Hilde Hylland
    Harritshoj, Lene Holm
    Christensen, Vibeke Brix
    Ifversen, Marianne
    PEDIATRIC BLOOD & CANCER, 2021, 68 (11)
  • [46] Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia
    Herrera, L.
    Stanciu-Herrera, C.
    Morgan, C.
    Ghetie, V.
    Vitetta, E. S.
    LEUKEMIA & LYMPHOMA, 2006, 47 (11) : 2380 - 2387
  • [47] High Response Rates Following Point-of-Care Anti-CD19 CAR T-Cell Therapy in Adults with Relapsed/Refractory Acute B Lymphoblastic Leukemia
    Fried, Shalev
    Danylesko, Ivetta
    Marcus, Ronit
    Itzhaki, Orit
    Yerushalmi, Ronit
    Shem-Tov, Noga
    Sdayoor, Inbal
    Shouval, Roni
    Jacoby, Elad
    Kedmi, Meirav
    Nagler, Arnon
    Shimoni, Avichai
    Avigdor, Abraham
    BLOOD, 2023, 142
  • [48] Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features
    Zhang, Xian
    Lu, Xin-an
    Yang, Junfang
    Zhang, Gailing
    Li, Jingjing
    Song, Lisong
    Su, Yunchao
    Shi, Yanze
    Zhang, Min
    He, Jiujiang
    Song, Dan
    Lv, Fanyong
    Li, Wenqian
    Wu, Yan
    Wang, Hui
    Liu, Hongxing
    Zhou, Xiaosu
    He, Ting
    Lu, Peihua
    BLOOD ADVANCES, 2020, 4 (10) : 2325 - 2338
  • [49] A Feasibility and Safety Study of Non-Viral Genome Targeting Anti-CD19 CAR-T in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
    Wang, Yi
    Wang, Hui
    Gao, Ying
    Zhang, Ding
    Zheng, Yan
    Hu, Xingxing
    Gao, Qiuying
    Peng, Zuohan
    Li, Le
    Niu, Ben
    Hou, Limin
    Wang, Ling
    Zhang, Weihua
    Zhang, Yi
    Ru, Xingli
    BLOOD, 2020, 136
  • [50] Outcomes of Second Anti-CD19 CAR T-Cell Therapy (CART2) in Acute B Lymphoblastic Leukemia and the Impact of Allo-HSCT on Efficacy
    Xu, Qianwen
    Shi, Yi
    Xue, Lei
    An, Furun
    Xu, Hui
    Liu, Xin
    Zhu, Xiaoyu
    Sun, Zimin
    Zhai, Zhimin
    Wang, Xingbing
    CELL TRANSPLANTATION, 2023, 32